Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$2.02 - $3.14 $836 - $1,299
-414 Reduced 14.9%
2,365 $5,000
Q4 2023

Feb 14, 2024

SELL
$1.59 - $3.85 $4,905 - $11,877
-3,085 Reduced 52.61%
2,779 $9,000
Q3 2023

Nov 14, 2023

BUY
$3.74 - $5.45 $6,773 - $9,869
1,811 Added 44.68%
5,864 $21,000
Q2 2023

Aug 10, 2023

BUY
$3.79 - $8.3 $15,360 - $33,639
4,053 New
4,053 $17,000
Q4 2022

Jun 14, 2023

BUY
$5.69 - $10.07 $24,176 - $42,787
4,249 New
4,249 $33.7 Million
Q3 2022

Jun 14, 2023

BUY
$7.17 - $13.87 $30,465 - $58,933
4,249 New
4,249 $40.8 Million
Q2 2022

Jun 20, 2023

BUY
$5.86 - $13.23 $24,899 - $56,214
4,249 New
4,249 $30,000
Q1 2022

Jun 20, 2023

BUY
$10.92 - $16.41 $46,399 - $69,726
4,249 New
4,249 $54,000
Q1 2022

Mar 30, 2023

SELL
$10.92 - $16.41 $148,118 - $222,585
-13,564 Reduced 76.15%
4,249 $54,000
Q1 2022

May 12, 2022

SELL
$10.92 - $16.41 $148,118 - $222,585
-13,564 Reduced 76.15%
4,249 $55,000
Q4 2021

Jun 21, 2023

BUY
$15.81 - $18.99 $281,623 - $338,268
17,813 New
17,813 $284,000
Q3 2021

Jun 21, 2023

BUY
$12.68 - $17.79 $225,868 - $316,893
17,813 New
17,813 $286,000
Q2 2021

Mar 30, 2023

BUY
$12.95 - $15.41 $24,864 - $29,587
1,920 Added 12.08%
17,813 $246,000
Q2 2021

Aug 16, 2021

BUY
$12.95 - $15.41 $230,471 - $274,251
17,797 Added 111231.25%
17,813 $246,000
Q1 2021

Jun 26, 2023

BUY
$14.42 - $21.39 $229,177 - $339,951
15,893 New
15,893 $232 Million
Q1 2021

Mar 30, 2023

BUY
$14.42 - $21.39 $167,906 - $249,065
11,644 Added 274.04%
15,893 $232,000
Q1 2021

May 14, 2021

BUY
$14.42 - $21.39 $230 - $342
16 New
16 $232,000
Q4 2020

Jun 22, 2023

BUY
$16.56 - $18.94 $294,585 - $336,923
17,789 New
17,789 $309 Million
Q3 2020

Jun 26, 2023

BUY
$17.41 - $19.89 $309,706 - $353,823
17,789 New
17,789 $326 Million
Q2 2020

Jun 26, 2023

BUY
$14.43 - $19.16 $292,842 - $388,833
20,294 New
20,294 $362 Million
Q1 2020

Jul 12, 2023

BUY
$11.67 - $22.53 $236,830 - $457,223
20,294 New
20,294 $329 Million
Q4 2019

Jul 12, 2023

BUY
$16.33 - $21.37 $325,799 - $426,352
19,951 New
19,951 $359 Million
Q3 2019

Jul 12, 2023

BUY
$16.3 - $23.37 $338,143 - $484,810
20,745 New
20,745 $420 Million
Q2 2019

Jul 12, 2023

BUY
$13.1 - $22.1 $223,630 - $377,269
17,071 New
17,071 $377 Million
Q1 2019

Jul 13, 2023

BUY
$8.38 - $15.5 $143,054 - $264,600
17,071 New
17,071 $233 Million
Q4 2018

Jul 13, 2023

BUY
$8.65 - $16.28 $147,664 - $277,915
17,071 New
17,071 $154 Million
Q3 2018

Jul 13, 2023

BUY
$14.45 - $20.25 $229,335 - $321,387
15,871 New
15,871 $262 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $122M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.